What is the recommended management of hyperthyroidism, including antithyroid drug dosing, beta‑blocker use, monitoring, and options for pregnancy or definitive therapy?

Management of Hyperthyroidism

For hyperthyroidism in pregnancy, treat with thioamides (propylthiouracil or methimazole) targeting high-normal free T4 levels, add propranolol for immediate symptom control, and monitor free T4 or FTI every 2-4 weeks. 1

Initial Pharmacologic Management

Antithyroid Drug Selection and Dosing

• Use thioamides as first-line therapy with the goal of maintaining FT4 or FTI in the high-normal range using the lowest possible dosage 1
• Both propylthiouracil and methimazole are effective options with similar fetal outcomes in recent studies 1
• Methimazole is generally preferred outside pregnancy due to longer half-life and fewer severe side effects 2
• However, propylthiouracil is recommended during first trimester due to methimazole's association with neonatal malformations, with switch to methimazole thereafter to reduce hepatotoxicity risk 3, 4

Beta-Blocker Use for Symptom Control

• Add a beta-blocker (e.g., propranolol) for immediate symptom relief while waiting for thioamide therapy to reduce thyroid hormone levels 1
• Both beta-1 selective beta-blockers and propranolol are viable options with similar mortality outcomes 5
• Beta-blockers may be the only treatment needed for transient thyroiditis 6

Monitoring Strategy

Frequency and Parameters

• Monitor FT4 or FTI every 2-4 weeks during active treatment to ensure maintenance in high-normal range 1
• In pregnancy, TSH and FT4 or FTI testing should be performed when hyperthyroidism is suspected 1
• Monitor for agranulocytosis - if sore throat and fever develop, obtain complete blood count immediately and discontinue thioamide 1
• Watch for other side effects including hepatitis, vasculitis, and thrombocytopenia 1

Common Pitfalls

Recent population-based data reveals that thyroid monitoring in pregnancy is suboptimal - TSH was measured in only 53.1% of pregnancies with hyperthyroidism, and 28.1% showed suboptimal thyroid status 7. This highlights the critical need for systematic monitoring protocols.

Management During Pregnancy

Special Considerations

• Pregnant women with hyperthyroidism face increased risks of severe preeclampsia, preterm delivery, heart failure, miscarriage, and low birth weight if inadequately treated 1
• Women treated with propylthiouracil or methimazole can breastfeed safely 1
• Fetal thyroid suppression from thioamides is usually transient and rarely requires treatment 1
• Monitor fetal heart rate and growth; ultrasound screening for fetal goiter is not necessary unless problems detected 1
• Alert the newborn's physician about maternal Graves' disease due to risk of neonatal thyroid dysfunction 1

Pregnancy-Specific Drug Switching

In clinical practice, 32.6% of first-trimester carbimazole-exposed pregnancies are switched to propylthiouracil, while 6.0% of propylthiouracil-exposed pregnancies switch to carbimazole 7. This reflects the evolving understanding of teratogenic risks.

Definitive Therapy Options

Surgical Management

• Thyroidectomy should be reserved for women who do not respond to thioamide therapy 1
• If surgery is necessary during pregnancy, perform preferably during second trimester 1
• In non-pregnant patients with apparently intractable Graves' disease and large goiter (>40 g), consider radioactive iodine therapy 8

Radioactive Iodine Considerations

• Radioactive iodine (I-131) is absolutely contraindicated in pregnant women 1
• If inadvertent exposure occurred before 10 weeks gestation, fetal thyroid is unlikely to have been ablated 1
• Exposure after 10 weeks requires counseling about risk of congenital hypothyroidism and pregnancy continuation 1
• Women should not breastfeed for 4 months after I-131 treatment 1

Important Caveat About Definitive Treatment

Pregnancies with prior definitive treatment (thyroidectomy or radioiodine) are significantly more likely to have suboptimal thyroid status compared with pregnancies starting during antithyroid drug treatment (odds ratio 4.72) 7. This underscores the need for enhanced monitoring in women with prior definitive therapy who become pregnant.

Thyroid Storm Management

Recognition and Treatment

• Thyroid storm is a medical emergency characterized by fever, tachycardia disproportionate to fever, altered mental status, vomiting, diarrhea, and cardiac arrhythmia 1
• Do not delay treatment for test results - begin therapy immediately based on clinical presentation 1
• Standard drug regimen includes: propylthiouracil or methimazole; saturated solution of potassium iodide or sodium iodide; dexamethasone; and phenobarbital 1
• Provide general supportive measures including oxygen, antipyretics, and appropriate monitoring 1
• Avoid delivery during thyroid storm unless deemed necessary 1

Long-Term Antithyroid Drug Therapy

For patients who prefer medical management over definitive therapy, evidence supports that ≥5 years of ATD treatment is accompanied by remission in the majority of patients with Graves' hyperthyroidism 9. Median time to remission is 6.8 years, with 55% achieving remission, though some patients require lifelong treatment 8.